A Phase I First-In-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients With Advanced Cancer

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-12-0098
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

A Phase I First-In-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2015English

First-In-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-Her3 Monoclonal Antibody, in Patients With Metastatic or Advanced HER3-Positive Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2015English

Anti-Pd-1 Monoclonal Antibody MEDI0680 in a Phase I Study of Patients With Advanced Solid Malignancies

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2019English

Anti-Tumour Activity of a First-In-Class Agent NUC-1031 in Patients With Advanced Cancer: Results of a Phase I Study

British Journal of Cancer
Cancer ResearchOncology
2018English

First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2014English

A First-In-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination With Erlotinib in Advanced Cancer

Clinical Cancer Research
Cancer ResearchOncology
2016English

Phase I Study of Temozolomide in Paediatric Patients With Advanced Cancer

British Journal of Cancer
Cancer ResearchOncology
1998English

First‐in‐human Phase I Study of E7090, a Novel Selective FGFR Inhibitor, in Patients With Advanced Solid Tumors

Cancer Science
Cancer ResearchMedicineOncology
2020English

Phase I Study of Anti-Cd3 X Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients

Prostate Cancer
Cancer ResearchOncologyUrology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy